There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Leurocristine Sulfate is an inhibitor for polymerization of microtubules with IC50 value of 32μM. It inhibited assembly-end addition with IC50 value of 0.085μM and exhibited 50% cell proliferation inhibition effect shown as >2 fold compared with vinblastine. Besides, the inhibitor could decrease the tumor growth in L-cells with a ratio of 57% compared to non-drug treatment control which could also be potential to inhibit cell proliferation and tumor production in B16 melanoma cells. In HepG2.2.15 and HepG2-HBV1.1 cells, 0.1 μM Leurocristine showed no significant cytotoxicity to both of them. HBV DNA copies were up-regulated by 4 fold and 5.6 fold in the two cells, respectively. Meanwhile, the secretion of HBV DNA copies and the expression of HBV pgRNA were improved. The intracellular HBsAg and HBcAg expression were also increased significantly. Most importantly, Leurocristine at 0.1μM also declined the proliferation rate by 60% in the stable HBV-expressing cell lines while it was 55% in the two cells mentioned above. This compound could also induce cell cycle arrest at S-phase while decrease the numbers of cells at G1/G0 and G2/M phases. SH-SY5Y cells treated with 0.1μM Leurocristine for different time caused decrease of the percentage of G0 /G1 phase cells gradually from 76.26% to 16.46%, while the percentage of G2/M phase cells increased gradually from 20.60% to 72.34%. The percentage of cells at sub-G1 phase increased from 5.75% to 21.25%. These treated SH-SY5Y cells also exhibited distinct changes in the microtubular structure by causing cell cycle arrest at the M phase and time-course premature termination of mitosis .
Vincristine sulfate/硫酸长春新碱 细胞实验
Cell Line
Concentration
Treated Time
Description
References
MCF7/VP cells
5 μM
18 h
To test the sensitivity of MCF7/VP cells to Vincristine in the presence of pyrazolopyrimidines, results showed that CBLC4H10, CBLC4E10, and CBLC4E11 significantly increased the sensitivity of cells to Vincristine by 14.6, 11.8, and 10.4 fold respectively.
Cancer Res. 2009 Aug 15;69(16):6573-80.
RD
3 × 10^-12 −1 × 10^-8 M
The combination of Rapamycin with Vincristine showed sub-additive effects in RD cells, with an EC50 ratio of 1.66, p<0.0001.
Mol Cancer Ther. 2010 Jan;9(1):101-12.
Rh41
3 × 10^-12 −1 × 10^-8 M
The combination of Rapamycin with Vincristine showed sub-additive effects in Rh41 cells, with an EC50 ratio of 1.42, p=0.0009.
Mol Cancer Ther. 2010 Jan;9(1):101-12.
MDA-MB-231 cells
1 µM
24 h
To study the cytotoxicity of Vincristine in the presence of stress hormones. Results showed that the cytotoxicity of Vincristine was significantly reduced in the presence of stress hormones.
Br J Cancer. 2015 Apr 28;112(9):1461-70.
RL B cell lymphoma cells
2 µM
12 h
Low-dose Vincristine combined with T-oligo induced apoptosis in B cell lymphoma cells in vitro, with a greater-than-additive effect compared to either agent alone.
Int J Cancer. 2009 Jan 15;124(2):473-82.
TC-32MRP-1.Fb-neo cells
2–120 nM
48 h
To evaluate the effect of MRP-1 overexpression on cell viability, results showed that MRP-1 overexpression increased resistance to vincristine and etoposide.
Br J Cancer. 2012 Mar 13;106(6):1224-33.
US.7 cells
2.5 nM
6 days
To study the effect of combining Vincristine with AMD11070, results showed that the combination delayed the emergence of resistant cells
Leukemia. 2011 Aug;25(8):1314-23.
Vincristine sulfate/硫酸长春新碱 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
HMYCN transgenic mice
Intraperitoneal injection
0.2 mg/kg
Daily for 5 consecutive days
To evaluate the therapeutic effect of Reversan in combination with Vincristine on neuroblastoma, results showed that the combination significantly prolonged the survival time of mice, with Vincristine alone increasing survival by ~10 days, and the combination increasing survival by an additional 20 days.
Cancer Res. 2009 Aug 15;69(16):6573-80.
Mice
Subcutaneous tumor xenograft model
Intraperitoneal injection
1 mg/kg
Once a week for 6 weeks
The combination of Rapamycin with Vincristine showed therapeutic enhancement in 4 out of 11 evaluable xenograft models.
Mol Cancer Ther. 2010 Jan;9(1):101-12.
Mice
4T1 mammary tumor model
Intravenous
1 mg/kg
Day 7 and 12
To evaluate the effect of Vincristine on MDSC, the results showed limited efficacy in depleting MDSC.
To mimic the first-line chemotherapy regimen for high-risk neuroblastoma and evaluate treatment efficacy. Results showed varied responses to the COJEC treatment protocol across different PDX models, ranging from no response to complete remission.
Sci Adv. 2022 Oct 28;8(43):eabq4617
Mice
Diffuse large B-cell lymphoma (DLCL) model
Intravenous injection
0.5 mg/kg
6 days
Vincristine combined with T-oligo significantly reduced tumor burden in lymphoma mice in vivo, with a greater-than-additive effect compared to either agent alone.
To study the therapeutic effect of combining Vincristine with AMD11070 on ALL, results showed that the combination significantly prolonged survival and reduced leukemia cell burden
搜索
HazMat Fee +
